MiNK Therapeutics (NASDAQ:INKT) said it is advancing its off-the-shelf invariant natural killer T cell therapy platform into ...
Randomized Phase 2 trial evaluates off-the-shelf invariant natural killer T (iNKT) cell therapy in patients with acute lung ...
Randomized Phase 2 trial initiated for agenT-797 in severe acute lung injury and respiratory distress, with preliminary data ...
1don MSN
MiNK outlines 90-patient randomized phase II ARDS trial with initial data expected in 2H 2026
Q1 2026 Management View Dr. Jennifer Buell (Co-Founder, President, CEO & Director) framed recent disclosures around clinical and mechanistic readouts across oncology and pulmonary indications, saying, ...
Health officials in the US are monitoring 41 potential hantavirus cases across 12 states, prompting federal response and ...
The state assessed a $43,000 penalty following a medication error and also criticized the hospital’s handling of emergency ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results